Cadrenal Therapeutics, Inc. stock is up 25.26% since 30 days ago. The next earnings date is Sep 19, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 December’s closed higher than November. 100% of analysts rate it a buy.
We are focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Our principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida.